Octaplex

Human Coagulation Factor IX, the active ingredient in Octaplex, is a coagulation factor presented as a sterile injectable solution for intravenous use. It is used to replace deficient clotting factors in patients with hemophilia B and other related bleeding disorders. GNH USA supplies Octaplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Octaplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Octaplex is a plasma‑derived coagulation concentrate that acts on the intrinsic pathway of the clotting cascade.

- Hemophilia B: Provides functional Factor IX to control and prevent bleeding episodes. - Acquired Factor IX deficiency: Restores clotting ability in patients with deficiency due to liver disease or vitamin K antagonist therapy. - Peri‑operative management: Supplies necessary clotting activity for patients undergoing surgery who have low Factor IX levels. - Congenital Factor IX deficiency (rare): Supports hemostasis in genetically deficient individuals. - Trauma‑induced bleeding: Helps achieve hemostasis when severe bleeding is associated with low Factor IX activity.

Octaplex may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Injection site erythema: Redness and mild discomfort at the infusion site. - Headache: Transient mild headache reported after infusion. - Nausea: Occasional mild nausea during or after administration. - Fever: Low‑grade temperature elevation within 24 hours post‑infusion. - Mild arthralgia: Joint discomfort without swelling.

Serious or Rare Side Effects: - Anaphylaxis: Acute, potentially life‑threatening allergic reaction requiring immediate medical intervention. - Thromboembolic events: Formation of clots in veins or arteries, especially with high plasma concentrations. - Hemolytic transfusion reaction: Immune‑mediated destruction of red blood cells. - Viral transmission risk: Potential for transmission of blood‑borne pathogens despite viral inactivation steps. - Severe hypotension: Sudden drop in blood pressure during infusion. - Disseminated intravascular coagulation: Widespread activation of clotting leading to bleeding and organ dysfunction.

Octaplex should be used with careful clinical monitoring and adherence to handling guidelines.

- Allergy assessment: Verify no known hypersensitivity to human plasma proteins before administration. - Thrombotic risk: Evaluate patient history for thrombosis before high‑dose or repeated infusions. - Hepatic impairment: Adjust monitoring in patients with liver disease affecting clotting factor synthesis. - Concomitant anticoagulants: Use caution when patients are receiving warfarin or other anticoagulants. - Pediatric use: Dose and monitoring requirements differ; follow specialist guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplex can interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid): - Direct oral anticoagulants (DOACs): May counteract the pro‑coagulant effect of Factor IX replacement. - High‑dose aspirin or NSAIDs: Increase bleeding risk when combined with Factor IX deficiency.

Moderate Interactions (Monitor Closely): - Warfarin: Requires careful INR monitoring as Factor IX may alter anticoagulant effect. - Immunosuppressive biologics: May modify immune response to plasma‑derived proteins. - Vaccines: Observe for enhanced local reactions when administered near infusion time. - Antibiotics (e.g., vancomycin): Potential for additive infusion‑related reactions. - Other plasma‑derived concentrates: Cumulative clotting factor load may raise thrombotic risk.